Altimmune Board of Directors Appoints Jerry Durso as Chairman
August 11, 2025
Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Altimmune, Inc., a late clinical-stage biopharmaceutical company
